CoChat

Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12

Lewis, Nuruddeen D., Sia, Chang Ling, Kirwin, Katherine, Haupt, Sonya, Mahimkar, Gauri, Zi, Tong, Xu, Ke, Dooley, Kevin, Jang, Su Chul, Choi, Bryan, Boutin, Adam, Grube, Andrew, McCoy, Christine, Sanchez-Salazar, Jorge, Doherty, Michael, Gaidukov, Leonid, Estes, Scott, Economides, Kyriakos D., Williams, Douglas E., Sathyanarayanan, Sriram · 2021 · Molecular Cancer Therapeutics
Cited by 106

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The promise of IL12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL12, a novel, engineered exosome therapeutic that displays functional IL12 on the surface of an exosome. IL12 exosomal surface expression was achieved via fusion to the abundant exosomal surface protein PTGFRN resulting in equivalent potency in vitro to recombinant IL12 (rIL12) as demonstrated by IFNγ production. Following intratumoral injection, exoIL12 exhibited prolonged tumor retention and greater antitumor activity than rIL12. Moreover, exoIL12 was significantly more potent than rIL12 in tumor growth inhibition. In the MC38 model, complete responses were observed in 63% of mice treated with exoIL12; in contrast, rIL12 resulted in 0% complete responses at an equivalent IL12 dose. This correlated with dose-dependent increases in tumor antigen–specific CD8+ T cells. Rechallenge studies of exoIL12 complete responder mice showed no tumor regrowth, and depletion of CD8+ T cells completely abrogated antitumor activity of exoIL12. Following intratumoral administration, exoIL12 exhibited 10-fold higher intratumoral exposure than rIL12 and prolonged IFNγ production up to 48 hours. Retained local pharmacology of exoIL12 was further confirmed using subcutaneous injections in nonhuman primates. This work demonstrates that tumor-restricted pharmacology of exoIL12 results in superior in vivo efficacy and immune memory without systemic IL12 exposure and related toxicity. ExoIL12 is a novel cancer therapeutic candidate that overcomes key limitations of rIL12 and thereby creates a therapeutic window for this potent cytokine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-20-0484

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 106

Metadata

Authors
Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B., Boutin, A., Grube, A., McCoy, C., Sanchez-Salazar, J., Doherty, M., Gaidukov, L., Estes, S., Economides, K. D., Williams, D. E., & Sathyanarayanan, S.
Venue
Molecular Cancer Therapeutics
Published
2021-03-01
Volume
20
Issue
3
Pages
523-534
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3116104321
Cited by
106
References
4
FWCI
3.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. https://app.cochat.ai/papers/10.1158/1535-7163.mct-20-0484
The paper
Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B., Boutin, A., Grube, A., McCoy, C., Sanchez-Salazar, J., Doherty, M., Gaidukov, L., Estes, S., Economides, K. D., Williams, D. E., & Sathyanarayanan, S. (2021). Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-20-0484

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.